니페디핀 시장 : 투여형별, 적응증별, 유통 채널별, 지역별

Nifedipine Medication Market is estimated to be valued at USD 1,256.7 Mn in 2025 and is expected to reach USD 2,357.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.

Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.

Market Dynamics:

A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.

Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet's robust portfolio of generic oral solid products.

However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global nifedipine medication market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global nifedipine medication market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited , Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division) Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd, and Apotex
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global nifedipine medication market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nifedipine medication market

Global Nifedipine Medication Market Detailed Segmentation:

• By Dosage Form:
  • Tablets
  • Extended-release Tablets
  • Capsules
  • Others (Sublingual tablets/spray, Patches and Others)
• By Indication:
  • Hypertension
  • Angina Pectoris
  • Raynaud's Phenomenon
  • Others (Pre-term labor, vasospastic conditions and Others)
• By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sanofi S.A.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz International GmbH (a Novartis division)
  • Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Dosage Form
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Key Highlights
• Regulatory Scenario
• Recent Trends
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Mergers, Acquisitions, and Collaborations

4. Global Nifedipine Medication Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Nifedipine Medication Market, By Dosage Form, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Extended-Release Tablets
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Capsules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Sublingual tablets/spray, Patches and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Nifedipine Medication Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hypertension
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Angina Pectoris
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Raynaud's Phenomenon
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Pre-term labor, vasospastic conditions and Others)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Nifedipine Medication Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. 8. Global Nifedipine Medication Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Sub-region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Company Profile
  • Pfizer Inc
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Novartis AG
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Merck & Co., Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • AstraZeneca PLC
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Teva Pharmaceutical Industries Ltd
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Mylan N.V.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sanofi S.A.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Johnson & Johnson
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • GlaxoSmithKline plc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Lupin Limited
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sun Pharmaceutical Industries Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Sandoz International GmbH (a Novartis division)
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Dr. Reddy's Laboratories Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Torrent Pharmaceuticals Ltd.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Apotex Inc.
• Company Highlights
• Product Portfolio
• Key Developments
• Financial Performance
• Strategies
  • Analyst Views

10. Section

• References
• Research Methodology
• About us